Developer docs
API playgroundTry for free, no card

Search company profiles

Cherry Biotech

Full company profile

uuid0002m87

Namestring
Cherry Biotech
Legal namestring
Cherry Biotech (Société par actions simplifiée)
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cherry Biotech is a French biomedical technology company founded in 2015 and headquartered in Montreuil (Paris), organized as a Société par actions simplifi\u00e9e (SAS). It develops instruments and consumables for drug discovery and personalized medicine, with a stated mission to replace animal testing by combining microfluidic organ-on-chip technology, multi-omics, advanced live-cell imaging, and AI-driven analysis. The company has approximately 16 employees across 11 nationalities, supported by a leadership team that includes Co-Founder and CSO Dr. Thomas Gu\u00e9rinier and R&D lead Dr. Pierre Gaudriault.

The company's core product is the CubiX Platform, a scalable and customizable microenvironment controller fully compatible with live imaging, enabling organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and simultaneous control of temperature, medium flow, O2, N2, and CO2. CubiX is currently in pre-sales. Building on CubiX, Cherry Biotech sells the OrganoidPlate consumable family (AdipoPlate for adipose tissue, HepatoPlate for liver co-culture, and CanceroPlate variants for breast and lung cancer) and SmartSphero Plates (microstructured hydrogels for standardized spheroid formation in a "Pipet & Go" workflow). The CherryTemp instrument provides ultra-fast temperature shifts in the 5\u201345\u00b0C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast studies. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on the CubiX platform, and the company offers a 3D In Vitro Contract Research Organization (CRO) service for drug developers needing rapid access to organoid technology without capital investment in equipment.

Cherry Biotech serves pharmaceutical companies (Novo Nordisk, Sanofi), biotech firms, academic and translational research institutions (Gustave Roussy, Amsterdam UMC, Vrije Universiteit Brussel, Bielefeld University, CRG, IDIBAPS, CSIC), and CROs/CDMOs. Revenue streams include quote-based hardware and consumable sales, CRO services, and substantial non-dilutive EU public funding (H2020, EIC Transition 2022 / Project I.D.E.F.I.X, EIC Accelerator 2024 / Project ASTEROID, BPI France I-Lab / HOMO CHIPIEN, Eurostars / I-Bracelet, Euronanomed3 / Nano4Stroke, R\u00e9gion Bretagne / CHERRY360 and SpOC). Distribution is direct and consultative via a "Speak with our expert" contact form, supplemented by EU-funded scientific collaborations that serve as co-development channels and the December 2025 Atelerix partnership that enables non-cryogenic global shipping of organoid models. Pricing is not publicly disclosed across any product or service line.

Short descriptiontext

Cherry Biotech is a French biomedical technology company that develops organ-on-chip platforms (CubiX), ready-to-use organoid consumables (OrganoidPlate family, SmartSphero Plates), and 3D in vitro CRO services to deliver human-relevant preclinical drug testing for pharmaceutical companies, biotech firms, cancer centers, and academic research institutions as an alternative to animal testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip technology, 3D cell culture, microfluidic instruments, organoid models, preclinical drug testing
Industry2 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Organ-on-Chip Instruments
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
13D In Vitro Contract Research Organization (CRO) Services
TypeProfessional Services
Description

Standard and customized in vitro studies provided as a service to screen new therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers requiring rapid access to organoids and 3D cell-culture technology without investing in their own equipment. Includes a dedicated service menu.

cherrybiotech.com
2Hardware & Consumable Product Sales (CubiX, CherryTemp, OrganoidPlate, SmartSphero Plates)
TypeHardware Sales
Description

Direct sales of proprietary hardware platforms (CubiX microenvironment controller, CherryTemp temperature shift device) and consumable plate products (OrganoidPlate ready-to-use organoids including AdipoPlate, HepatoPlate, CanceroPlate lines; SmartSphero Plates microstructured hydrogels). CubiX is in pre-sales phase.

cherrybiotech.com
3EU & French Public Research Grants
TypeLicensing Royalties
Description

Funding from European Union programs (H2020, EIC Accelerator 2024, EIC Transition 2022, EIC Pathfinder) and French programs (BPI France I-Lab, Région Bretagne, Eurostars, Euronanomed3). White paper on animal testing was funded by EU under grant agreement n° 101046928 & 101046928.

cherrybiotech.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing for all products and services; no public price list
ModelOther
Notes

Prospective customers are directed to "Speak with our expert" and submit a contact form. Free consultation offered for CubiX projects. Pricing for CubiX, OrganoidPlate, SmartSphero Plates, CherryTemp, and 3D CRO services is not listed online.

cherrybiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1CubiX
Description

Microenvironment controller platform for organoids and live cell imaging; flagship product of the company.

cherrybiotech.com
+3 more records
Core offering1 text field

Cherry Biotech develops and sells the CubiX Platform, a microfluidic microenvironment controller fully compatible with live imaging that enables organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, gas (N2, CO2, O2), and medium flow without an incubator. The company sells ready-to-use organoid consumables (OrganoidPlate family including AdipoPlate, HepatoPlate, CanceroPlate Breast and Lung lines), SmartSphero Plates for standardized spheroid formation, and the CherryTemp ultra-fast temperature-shift device. It also offers 3D In Vitro Contract Research Organization (CRO) services for drug developers needing organoid and 3D cell-culture access without purchasing equipment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Global organ-on-chip market projected to grow from USD 134.9 million (2023) to USD 1,424.0 million by 2031 at 34.7% CAGR, with liver-on-a-chip holding the largest market share.
+3 more records
Product overview1 text field

Cherry Biotech operates a platform-plus-modules architecture centered on 3D cell culture and organ-on-chip technology. The CubiX Platform is the core instrument: a customizable microenvironment controller compatible with live imaging that allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, medium flow, O2, N2 and CO2. Building on CubiX, the company sells ready-to-use consumable products: the OrganoidPlate family (with sub-products AdipoPlate for adipose tissue, HepatoPlate for liver, and CanceroPlate for breast and lung cancer) and SmartSphero Plates for standardized spheroid formation. The CherryTemp instrument provides ultra-fast temperature shifts in the 5–45°C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on CubiX. Alongside products, Cherry Biotech offers a 3D In Vitro CRO service for drug developers who need rapid access to organoid/3D cell-culture technology without purchasing equipment. The whole offering is positioned to replace animal testing by combining microfluidic organ-on-chip, multi-omics, advanced imaging, and AI-driven analysis.

Product and service5 records
1CubiX Platform
CategoryMicroenvironment Controller Instrument
Description

Scalable, highly customizable, user-friendly microenvironment controller fully compatible with live imaging, enabling mimicking of physiological and pathological culture conditions in vitro. Allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and provides simultaneous user control over temperature, medium flow, O2, N2, and CO2 without an incubator. Target customers are pharma, biotech, and academic research institutions.

2OrganoidPlate
CategoryOrganoid Consumables
Description

Assay-ready, mature and differentiated organoid plates that allow researchers to skip culture time and directly perform assays, providing ready-to-use 3D in vitro organoid models for pre-clinical drug testing. Includes AdipoPlate (adipose tissue), HepatoPlate (liver co-culture), CanceroPlate Breast, and CanceroPlate Lung variants.

3SmartSphero Plates
CategorySpheroid Formation Consumables
Description

Microstructured hydrogel plates designed for simple, standardized, and consistent spheroid formation. The hydrogel shape provides a microenvironment that enables cells to sediment and self-aggregate within hours, supporting a Pipet & Go organoid culture workflow.

4CherryTemp
CategoryTemperature Control Instrument
Description

Ultra-fast temperature-shift device for live-cell imaging, operating in the 5-45°C range. Includes dedicated application packs (Phase Separation Pack, C. Elegans Pack, Yeast Pack) for specific research use cases.

53D In Vitro CRO Service
CategoryContract Research Services
Description

Contract research organization service providing both standard and customized in vitro studies to screen therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers needing rapid access to organoids and 3D cell-culture technology without investing in their own equipment.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagship / High-Priority Commercial PartnershipTypeStrategic or Co-development PartnerAnnounced on2025-12-14
Description

Atelerix (UK biotech) and Cherry Biotech (France) announced a partnership to develop a non-cryogenic shipping technology for biological materials, specifically organoids. The collaboration aims to enable extended transport at ambient or controlled temperatures, reducing reliance on cold-chain logistics and improving global distribution capabilities. The initial 12-month trial will validate the technology's performance for potential commercial deployment. This agreement integrates Atelerix's non-cryogenic transport solutions with Cherry Biotech's advanced organoid models, facilitating global distribution without cold-chain logistics.

2Institut de Génétique et Développement de Rennes (IGDR)
Strategic tierCore Scientific Collaboration PartnerTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Co-coordinator of the SpOC (Spheroid On Chip) project (Région Bretagne transfert de technologies, 2017-2018). Cherry Biotech designed the microfluidic device and, in collaboration with IGDR's Y.Arlot team, applied it to drug development, particularly in the lead identification phase. The project aimed to cultivate kidney cancer cells spheroids for at least 5 days in a microfluidic device. Listed as a trusted partner in the homepage "They Trust Us" logo block.

cherrybiotech.com
Strategic tierTechnology / Equipment Ecosystem PartnerTypeTechnology or Integration
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block. Elveflow is a provider of microfluidic flow control systems and instruments, indicating a technology ecosystem relationship with Cherry Biotech's organ-on-chip platforms.

Strategic tierIndustry PartnerTypeStrategic or Co-development Partner
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block as "Inside-Therapeutics-Lipid-nanoparticle-manufacturing-partner", indicating a collaboration around lipid nanoparticle manufacturing relevant to Cherry Biotech's drug delivery and organoid applications.

Strategic tierIndustry PartnerTypeStrategic or Co-development Partner
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block.

Strategic tierTechnology / Industry PartnerTypeTechnology or Integration
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block. 4Dcell is a technology partner in the cell-based assay and microfluidic space, relevant to Cherry Biotech's organ-on-chip platforms.

Strategic tierTechnology / Industry PartnerTypeTechnology or Integration
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block.

Strategic tierIndustry / Cluster PartnerTypeStrategic or Co-development Partner
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block.

9Paris-Saclay Cancer Cluster (PSCC)
Strategic tierEcosystem / Cluster PartnerTypeGTM or Marketing Partner
Description

Listed as a trusted partner in the homepage "They Trust Us" logo block (logo_PSCC.png). Paris-Saclay Cancer Cluster is a major oncology innovation cluster in France, providing GTM and ecosystem support relevant to Cherry Biotech's cancer organoid and CubiX applications.

cherrybiotech.com
Strategic tierMarketing / Advertising PartnersTypeGTM or Marketing Partner
Description

Cherry Biotech uses Google Ads, LinkedIn Ads, and Facebook Pixel for advertising and retargeting per its Cookie Policy. These are marketing technology partners enabling paid acquisition.

11OVH
Strategic tierInfrastructure / Hosting PartnerTypeTechnology or Integration
Description

OVH is the hosting provider (Hébergeur) for the www.cherrybiotech.com website. OVH SAS, capital 10,000,000 €, RCS Roubaix – Tourcoing 424 761 419 00045. Cherry Biotech's data is hosted on European soil.

Strategic tierCompliance / Consulting PartnerTypeImplementation/ SI/ Consulting Partner
Description

Privacy Policy is "Certified compliant by Dipeeo®" - Dipeeo is a Data Protection Officer (DPO) consultancy, serving as Cherry Biotech's outsourced independent Data Protection Officer.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Emulate is the leading organ-on-chip company (Liver-Chip, Lung-Chip, etc.) and the most direct competitor to Cherry Biotech's CubiX platform, serving pharma R&D with similar in vitro microfluidic models for preclinical drug testing.

2CN Bio Innovations
TypeDirect peer
Description

CN Bio develops organ-on-chip platforms (PhysioMimix) targeting pharma and academic customers for liver, lung, and gut models — overlapping head-to-head with CubiX's positioning in drug discovery and NAMs.

TypeDirect peer
Description

MIMETAS provides organ-on-chip technology (OrganoPlate) and disease models for pharma and biotech preclinical research, directly comparable to Cherry Biotech's microfluidic organoid and CubiX offerings.

TypeDirect peer
Description

TissUse builds multi-organ-chip and single-organ-chip systems for drug development and cosmetics testing, directly competing in the same organ-on-chip and animal-replacement space as Cherry Biotech.

TypeDirect peer
Description

InSphero offers 3D microtissue and organoid solutions (liver, pancreatic islets, tumor spheroids) for drug discovery, comparable to Cherry Biotech's OrganoidPlate and SmartSphero Plate consumable products.

6Kirkstall
TypeDirect peer
Description

Kirkstall develops organ-on-chip and 3D cell culture systems (Quasi Vivo) for in vitro toxicology and drug testing, an adjacent organ-on-chip peer with similar pharma and cosmetics customer targets.

TypeEmerging player
Description

Organovo is a 3D biology and bioprinting company developing tissue models for preclinical research; its 3D tissue work overlaps thematically with Cherry Biotech's organoid and CubiX organ-model strategy.

TypeEmerging player
Description

CytoSMART provides live-cell imaging and image-analysis solutions, overlapping with Cherry Biotech's live-imaging and AI-driven organoid analysis capabilities on the CubiX platform.

TypeBroad incumbent
Description

Molecular Devices (Danaher) is a large life-sciences instrumentation incumbent supplying live-cell imaging and screening platforms that overlap with Cherry Biotech's imaging and 3D cell-culture workflow.

TypeBroad incumbent
Description

Sartorius is a global bioprocessing and lab-tools incumbent with cell-culture and lab-instrumentation products that serve many of the same pharma/biotech customers Cherry Biotech targets with CubiX and CRO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cherry Biotech

Organ-on-Chip Instrumentscherrybiotech.com

Cherry Biotech is a French biomedical technology company that develops organ-on-chip platforms (CubiX), ready-to-use organoid consumables (OrganoidPlate family, SmartSphero Plates), and 3D in vitro CRO services to deliver human-relevant preclinical drug testing for pharmaceutical companies, biotech firms, cancer centers, and academic research institutions as an alternative to animal testing.

What Cherry Biotech does

Cherry Biotech is a French biomedical technology company founded in 2015 and headquartered in Montreuil (Paris), organized as a Société par actions simplifi\u00e9e (SAS). It develops instruments and consumables for drug discovery and personalized medicine, with a stated mission to replace animal testing by combining microfluidic organ-on-chip technology, multi-omics, advanced live-cell imaging, and AI-driven analysis. The company has approximately 16 employees across 11 nationalities, supported by a leadership team that includes Co-Founder and CSO Dr. Thomas Gu\u00e9rinier and R&D lead Dr. Pierre Gaudriault.

The company's core product is the CubiX Platform, a scalable and customizable microenvironment controller fully compatible with live imaging, enabling organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and simultaneous control of temperature, medium flow, O2, N2, and CO2. CubiX is currently in pre-sales. Building on CubiX, Cherry Biotech sells the OrganoidPlate consumable family (AdipoPlate for adipose tissue, HepatoPlate for liver co-culture, and CanceroPlate variants for breast and lung cancer) and SmartSphero Plates (microstructured hydrogels for standardized spheroid formation in a "Pipet & Go" workflow). The CherryTemp instrument provides ultra-fast temperature shifts in the 5\u201345\u00b0C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast studies. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on the CubiX platform, and the company offers a 3D In Vitro Contract Research Organization (CRO) service for drug developers needing rapid access to organoid technology without capital investment in equipment.

Cherry Biotech serves pharmaceutical companies (Novo Nordisk, Sanofi), biotech firms, academic and translational research institutions (Gustave Roussy, Amsterdam UMC, Vrije Universiteit Brussel, Bielefeld University, CRG, IDIBAPS, CSIC), and CROs/CDMOs. Revenue streams include quote-based hardware and consumable sales, CRO services, and substantial non-dilutive EU public funding (H2020, EIC Transition 2022 / Project I.D.E.F.I.X, EIC Accelerator 2024 / Project ASTEROID, BPI France I-Lab / HOMO CHIPIEN, Eurostars / I-Bracelet, Euronanomed3 / Nano4Stroke, R\u00e9gion Bretagne / CHERRY360 and SpOC). Distribution is direct and consultative via a "Speak with our expert" contact form, supplemented by EU-funded scientific collaborations that serve as co-development channels and the December 2025 Atelerix partnership that enables non-cryogenic global shipping of organoid models. Pricing is not publicly disclosed across any product or service line.

Cherry Biotech firmographics

Firmographics
Name
Cherry Biotech
Legal name
Cherry Biotech (Société par actions simplifiée)
Website
https://cherrybiotech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cherry Biotech is a French biomedical technology company that develops organ-on-chip platforms (CubiX), ready-to-use organoid consumables (OrganoidPlate family, SmartSphero Plates), and 3D in vitro CRO services to deliver human-relevant preclinical drug testing for pharmaceutical companies, biotech firms, cancer centers, and academic research institutions as an alternative to animal testing.
Ownership category
akta.pro rank

Cherry Biotech industry classification

Industry
Product category
Organ-on-Chip Instruments
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Organ-on-chip technology
  • 3D cell culture
  • Microfluidic instruments
  • Organoid models
  • Preclinical drug testing

Where Cherry Biotech is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Cherry Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. 3D In Vitro Contract Research Organization (CRO) Services: Standard and customized in vitro studies provided as a service to screen new therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers requiring rapid access to organoids and 3D cell-culture technology without investing in their own equipment. Includes a dedicated service menu.
  2. Hardware & Consumable Product Sales (CubiX, CherryTemp, OrganoidPlate, SmartSphero Plates): Direct sales of proprietary hardware platforms (CubiX microenvironment controller, CherryTemp temperature shift device) and consumable plate products (OrganoidPlate ready-to-use organoids including AdipoPlate, HepatoPlate, CanceroPlate lines; SmartSphero Plates microstructured hydrogels). CubiX is in pre-sales phase.
  3. EU & French Public Research Grants: Funding from European Union programs (H2020, EIC Accelerator 2024, EIC Transition 2022, EIC Pathfinder) and French programs (BPI France I-Lab, Région Bretagne, Eurostars, Euronanomed3). White paper on animal testing was funded by EU under grant agreement n° 101046928 & 101046928.

Pricing tiers

ModelBillingPrice
Other—Quote-based pricing for all products and services; no public price list

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Cherry Biotech product offering

Product offering

Core offering

Cherry Biotech develops and sells the CubiX Platform, a microfluidic microenvironment controller fully compatible with live imaging that enables organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, gas (N2, CO2, O2), and medium flow without an incubator. The company sells ready-to-use organoid consumables (OrganoidPlate family including AdipoPlate, HepatoPlate, CanceroPlate Breast and Lung lines), SmartSphero Plates for standardized spheroid formation, and the CherryTemp ultra-fast temperature-shift device. It also offers 3D In Vitro Contract Research Organization (CRO) services for drug developers needing organoid and 3D cell-culture access without purchasing equipment.

Product overview

Cherry Biotech operates a platform-plus-modules architecture centered on 3D cell culture and organ-on-chip technology. The CubiX Platform is the core instrument: a customizable microenvironment controller compatible with live imaging that allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, medium flow, O2, N2 and CO2. Building on CubiX, the company sells ready-to-use consumable products: the OrganoidPlate family (with sub-products AdipoPlate for adipose tissue, HepatoPlate for liver, and CanceroPlate for breast and lung cancer) and SmartSphero Plates for standardized spheroid formation. The CherryTemp instrument provides ultra-fast temperature shifts in the 5–45°C range for live-cell imaging, with application packs for phase separation, C. elegans, and yeast. Specialized organ models (Adipose Tissue, Breast Cancer, Human Endothelialized Skin-on-Chip) run on CubiX. Alongside products, Cherry Biotech offers a 3D In Vitro CRO service for drug developers who need rapid access to organoid/3D cell-culture technology without purchasing equipment. The whole offering is positioned to replace animal testing by combining microfluidic organ-on-chip, multi-omics, advanced imaging, and AI-driven analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • CubiX: Microenvironment controller platform for organoids and live cell imaging; flagship product of the company.
  • CherryTemp
  • OrganoidPlate
  • SmartSphero Plate

Products and services

  • CubiX Platform Scalable, highly customizable, user-friendly microenvironment controller fully compatible with live imaging, enabling mimicking of physiological and pathological culture conditions in vitro. Allows organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, resident and circulating immunity, and provides simultaneous user control over temperature, medium flow, O2, N2, and CO2 without an incubator. Target customers are pharma, biotech, and academic research institutions.
  • OrganoidPlate Assay-ready, mature and differentiated organoid plates that allow researchers to skip culture time and directly perform assays, providing ready-to-use 3D in vitro organoid models for pre-clinical drug testing. Includes AdipoPlate (adipose tissue), HepatoPlate (liver co-culture), CanceroPlate Breast, and CanceroPlate Lung variants.
  • SmartSphero Plates Microstructured hydrogel plates designed for simple, standardized, and consistent spheroid formation. The hydrogel shape provides a microenvironment that enables cells to sediment and self-aggregate within hours, supporting a Pipet & Go organoid culture workflow.
  • CherryTemp Ultra-fast temperature-shift device for live-cell imaging, operating in the 5-45°C range. Includes dedicated application packs (Phase Separation Pack, C. Elegans Pack, Yeast Pack) for specific research use cases.
  • 3D In Vitro CRO Service Contract research organization service providing both standard and customized in vitro studies to screen therapeutic candidates, explore mechanisms of action, and accelerate clinical trial design. Particularly suitable for drug developers needing rapid access to organoids and 3D cell-culture technology without investing in their own equipment.

Quantifiable outcome

  • Global organ-on-chip market projected to grow from USD 134.9 million (2023) to USD 1,424.0 million by 2031 at 34.7% CAGR, with liver-on-a-chip holding the largest market share.
  • +3 more outcomes

Companies that use Cherry Biotech

Customer profile

Named customers7 records

Segments8 records

Ideal customer profiles5 records

Cherry Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature7 records

Cherry Biotech partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship / high-priority commercial partnership, core scientific collaboration partner, technology / equipment ecosystem partner, industry partner, technology / industry partner, industry / cluster partner, ecosystem / cluster partner, marketing / advertising partners, infrastructure / hosting partner and compliance / consulting partner.

  • Atelerixflagship / high-priority commercial partnershipStrategic or Co-development Partner · 14 December 2025Atelerix (UK biotech) and Cherry Biotech (France) announced a partnership to develop a non-cryogenic shipping technology for biological materials, specifically organoids. The collaboration aims to enable extended transport at ambient or controlled temperatures, reducing reliance on cold-chain logistics and improving global distribution capabilities. The initial 12-month trial will validate the technology's performance for potential commercial deployment. This agreement integrates Atelerix's non-cryogenic transport solutions with Cherry Biotech's advanced organoid models, facilitating global distribution without cold-chain logistics.
  • Institut de Génétique et Développement de Rennes (IGDR)core scientific collaboration partnerStrategic or Co-development Partner · 1 January 2017Co-coordinator of the SpOC (Spheroid On Chip) project (Région Bretagne transfert de technologies, 2017-2018). Cherry Biotech designed the microfluidic device and, in collaboration with IGDR's Y.Arlot team, applied it to drug development, particularly in the lead identification phase. The project aimed to cultivate kidney cancer cells spheroids for at least 5 days in a microfluidic device. Listed as a trusted partner in the homepage "They Trust Us" logo block.
  • Elveflowtechnology / equipment ecosystem partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block. Elveflow is a provider of microfluidic flow control systems and instruments, indicating a technology ecosystem relationship with Cherry Biotech's organ-on-chip platforms.
  • Inside Therapeuticsindustry partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block as "Inside-Therapeutics-Lipid-nanoparticle-manufacturing-partner", indicating a collaboration around lipid nanoparticle manufacturing relevant to Cherry Biotech's drug delivery and organoid applications.
  • Quimivitaindustry partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block.
  • 4Dcelltechnology / industry partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block. 4Dcell is a technology partner in the cell-based assay and microfluidic space, relevant to Cherry Biotech's organ-on-chip platforms.
  • Biosensetechnology / industry partnerTechnology or IntegrationListed as a trusted partner in the homepage "They Trust Us" logo block.
  • Groupe ICAREindustry / cluster partnerStrategic or Co-development PartnerListed as a trusted partner in the homepage "They Trust Us" logo block.
  • Paris-Saclay Cancer Cluster (PSCC)ecosystem / cluster partnerGTM or Marketing PartnerListed as a trusted partner in the homepage "They Trust Us" logo block (logo_PSCC.png). Paris-Saclay Cancer Cluster is a major oncology innovation cluster in France, providing GTM and ecosystem support relevant to Cherry Biotech's cancer organoid and CubiX applications.
  • Google, LinkedIn, Meta (Facebook)marketing / advertising partnersGTM or Marketing PartnerCherry Biotech uses Google Ads, LinkedIn Ads, and Facebook Pixel for advertising and retargeting per its Cookie Policy. These are marketing technology partners enabling paid acquisition.
  • OVHinfrastructure / hosting partnerTechnology or IntegrationOVH is the hosting provider (Hébergeur) for the www.cherrybiotech.com website. OVH SAS, capital 10,000,000 €, RCS Roubaix – Tourcoing 424 761 419 00045. Cherry Biotech's data is hosted on European soil.
  • Dipeeocompliance / consulting partnerImplementation/ SI/ Consulting PartnerPrivacy Policy is "Certified compliant by Dipeeo®" - Dipeeo is a Data Protection Officer (DPO) consultancy, serving as Cherry Biotech's outsourced independent Data Protection Officer.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Cherry Biotech competitors and assessment

Company assessment

Direct peers

  • Emulate: Emulate is the leading organ-on-chip company (Liver-Chip, Lung-Chip, etc.) and the most direct competitor to Cherry Biotech's CubiX platform, serving pharma R&D with similar in vitro microfluidic models for preclinical drug testing.
  • CN Bio Innovations: CN Bio develops organ-on-chip platforms (PhysioMimix) targeting pharma and academic customers for liver, lung, and gut models — overlapping head-to-head with CubiX's positioning in drug discovery and NAMs.
  • MIMETAS: MIMETAS provides organ-on-chip technology (OrganoPlate) and disease models for pharma and biotech preclinical research, directly comparable to Cherry Biotech's microfluidic organoid and CubiX offerings.
  • TissUse: TissUse builds multi-organ-chip and single-organ-chip systems for drug development and cosmetics testing, directly competing in the same organ-on-chip and animal-replacement space as Cherry Biotech.
  • InSphero: InSphero offers 3D microtissue and organoid solutions (liver, pancreatic islets, tumor spheroids) for drug discovery, comparable to Cherry Biotech's OrganoidPlate and SmartSphero Plate consumable products.
  • Kirkstall: Kirkstall develops organ-on-chip and 3D cell culture systems (Quasi Vivo) for in vitro toxicology and drug testing, an adjacent organ-on-chip peer with similar pharma and cosmetics customer targets.

Emerging players

  • Organovo: Organovo is a 3D biology and bioprinting company developing tissue models for preclinical research; its 3D tissue work overlaps thematically with Cherry Biotech's organoid and CubiX organ-model strategy.
  • CytoSMART: CytoSMART provides live-cell imaging and image-analysis solutions, overlapping with Cherry Biotech's live-imaging and AI-driven organoid analysis capabilities on the CubiX platform.

Broad incumbents

  • Molecular Devices: Molecular Devices (Danaher) is a large life-sciences instrumentation incumbent supplying live-cell imaging and screening platforms that overlap with Cherry Biotech's imaging and 3D cell-culture workflow.
  • Sartorius: Sartorius is a global bioprocessing and lab-tools incumbent with cell-culture and lab-instrumentation products that serve many of the same pharma/biotech customers Cherry Biotech targets with CubiX and CRO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Cherry Biotech social profiles

Digital presence

Cherry Biotech compliance and trust

Trust signal

Compliance2 records

Cherry Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cherry Biotech leadership team

Management profile

Number of profiles

Profiles3 records

Cherry Biotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cherry Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cherry Biotech

What does Cherry Biotech do?

Cherry Biotech develops and sells the CubiX Platform, a microfluidic microenvironment controller fully compatible with live imaging that enables organoid culture of up to 8 cell types for more than 28 days with a vascularized interface, controlling temperature, gas (N2, CO2, O2), and medium flow without an incubator. The company sells ready-to-use organoid consumables (OrganoidPlate family including AdipoPlate, HepatoPlate, CanceroPlate Breast and Lung lines), SmartSphero Plates for standardized spheroid formation, and the CherryTemp ultra-fast temperature-shift device. It also offers 3D In Vitro Contract Research Organization (CRO) services for drug developers needing organoid and 3D cell-culture access without purchasing equipment.

Is Cherry Biotech a public or private company?

Cherry Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cherry Biotech founded?

Cherry Biotech was founded in 2015. It employs 11 to 50 people.

Where is Cherry Biotech based?

Cherry Biotech is headquartered in Paris, France, in the Europe region.

How does Cherry Biotech make money?

Three revenue lines are on record. 3D In Vitro Contract Research Organization (CRO) Services are the primary driver. The others are hardware & Consumable Product Sales (CubiX, CherryTemp, OrganoidPlate, SmartSphero Plates) and EU & French Public Research Grants.

Who are Cherry Biotech's main competitors?

Direct peers on record are Emulate, CN Bio Innovations, MIMETAS, TissUse, InSphero and Kirkstall. Emerging players are Organovo and CytoSMART. Broad incumbents are Molecular Devices and Sartorius.

Does Cherry Biotech have an API?

No public API is recorded for Cherry Biotech.

What industry is Cherry Biotech in?

Cherry Biotech's product category is Organ-on-Chip Instruments. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SelectScienceAtelerix partners with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid modelsAtelerix has partnered with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models. This collaboration aims to improve the logistics and effectiveness of organoid research and applications. The advancement in transport solutions is crucial for enhancing the usability and accessibility of organoids in biomedical research.Longevity.TechnologyAtelerix and Cherry Biotech team up on organoid shippingUK-based biotech Atelerix has entered into a partnership with French organoid specialist Cherry Biotech to integrate hydrogel-based biosample transport technology with advanced 3D organoid models, addressing challenges in shipping temperature-sensitive biological materials without conventional cold-chain logistics. The collaboration begins with a 12-month trial period to validate technical performance and strategic fit, building on earlier testing that demonstrated preservation of membrane integrity and biological function during ambient or controlled-temperature transport. The companies aim to lower logistical barriers for laboratories lacking specialized cold-chain infrastructure, particularly in emerging research markets, while reducing costs and environmental footprint.News-MedicalAtelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid modelsAtelerix, a biotech company specializing in cell preservation and biological transport, has entered a partnership agreement with French company Cherry Biotech to integrate its patented hydrogel encapsulation technology with Cherry Biotech's advanced 3D organoid models for global shipment without cold-chain logistics. The initial 12-month trial period will validate the strategic and technical alignment of both companies while enabling worldwide distribution of temperature-sensitive organoid products including Cherry Biotech's recently released organoidPlate. The partnership aims to expand commercial traction and market reach for Atelerix's ambient logistics solutions while strengthening Cherry Biotech's ability to deliver cutting-edge organoid models to pharma and academic researchers globally.CherrybiotechCherry Biotech secures €2.5 million from the European Union for its organ-on-chip technology -Cherry Biotech, a TechBio startup developing organ-on-chip and organoid technologies, secured €2.5 million from the European Union. The company was selected for the EIC Accelerator program, which provides funding and support for innovative research.Microfluidics-Innovation-CenterOrgan-on-a-chip technology: innovations, applications, and future horizonsThis article provides a comprehensive review of organ-on-a-chip technology, detailing its applications in drug screening, disease modeling, and tissue engineering as an alternative to traditional animal testing. It examines various fabrication techniques such as soft lithography and 3D printing, while highlighting specific commercial products from companies like Microfluidic ChipShop, IVTech, IBIDI, and Cherry Biotech. The text further explores different organ models developed using this technology, including lung, gut, liver, and multi-organ systems.PR NewswireGlobal Organ-on-Chip Market Outlook to 2030, Featuring Key Players AxoSim Inc., Cherry Biotech, Emulate Inc. and Nortis Inc.ResearchAndMarkets.com has added the "Global Organ-on-Chip Market 2020-2030" report, forecasting the global organ-on-chip market to reach $420.6 million by 2030, growing at a compound annual growth rate of 33.5%. The market growth is driven by increasing adoption of organ-on-a-chip technology for early drug toxicity detection, rising demand for personalized medicine, the shift away from animal testing, and significant growth in research funding and venture capital investments. The report provides detailed market segmentation analysis across offering types, organ types, materials, applications, end users, and geographic regions, and profiles key vendors including market leaders and emerging players.